Related Experiment Video
Updated: Jan 29, 2026

Investigating the Effects of Probiotics on Pneumococcal Colonization Using an In Vitro Adherence Assay
Published on: April 28, 2014
Cost-Effectiveness Comparison of Pneumococcal Conjugate Vaccines in Turkish Children
Alen Marijam1, Jan Olbrecht1, Alev Ozakay2
1GSK, Wavre, Belgium.
Insights
Replacing the 13-valent pneumococcal conjugate vaccine (PCV13) with the pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Turkey is cost-effective. At equal prices, PHiD-CV is a dominant strategy, reducing acute otitis media cases and saving costs.
Area of Science:
- Public Health
- Vaccinology
- Health Economics
Background:
- The 13-valent pneumococcal conjugate vaccine (PCV13) is currently used for universal infant immunization in Turkey.
- Pneumococcal conjugate vaccines are crucial for preventing invasive pneumococcal disease, pneumonia, and acute otitis media (AOM) in children.
Purpose of the Study:
- To evaluate the cost-effectiveness of substituting PCV13 with the pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Turkey.
- To compare the health and economic impacts of PHiD-CV versus PCV13 for preventing pneumococcal diseases in infants.
Main Methods:
- A Markov cohort model simulated the outcomes for a cohort of infants over a 10-year period.
- Local epidemiological and economic data were incorporated, with a 3% annual discount rate applied to costs and benefits.
- The model assessed the impact on invasive pneumococcal disease, pneumonia, and AOM, including healthcare resource utilization.
Main Results:
- PHiD-CV demonstrated comparable effectiveness to PCV13 for meningitis and pneumonia, with a slight increase in bacteremia cases (+30).
- PHiD-CV led to significant reductions in AOM-related general practitioner visits (-34,955) and hospitalizations (-624).
- At price parity, PHiD-CV was found to be a dominant strategy, yielding 176 additional quality-adjusted life-years and saving €635,930.
Conclusions:
- Vaccine price is the primary determinant for choosing between PHiD-CV and PCV13 in Turkey.
- PHiD-CV represents a dominant and cost-effective strategy compared to PCV13 when vaccine prices are equal.
- The findings support the consideration of PHiD-CV for national immunization programs to optimize health outcomes and economic efficiency.
Background:
The 13-valent pneumococcal conjugate vaccine (PCV13) is used for universal infant vaccination in Turkey.
Objectives:
To assess the cost effectiveness of replacing PCV13 with pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).
Methods:
A Markov cohort model with monthly cycles following 1 cohort of infants over a 10-year time horizon was used. Local input parameters were obtained from published sources and expert consultation whenever possible. The model was adapted to estimate the health benefits and economic impact of each vaccine on invasive pneumococcal disease, pneumonia, and acute otitis media (AOM). An annual discount rate of 3% was used for benefits and costs (2016 euros).
Results:
Under base-case assumptions, vaccinating 1 birth cohort of 1 325 783 infants with PHiD-CV instead of PCV13 was predicted to have the same impact on meningitis and pneumonia, a similar impact on bacteremia (+30 cases), but greater reductions in AOM-related general practitioner visits (-34 955) and hospitalizations (-624). Assuming equal vaccine prices, PHiD-CV was predicted to be dominant over PCV13 (176 additional quality-adjusted life-years while saving €635 330 [discounted]). One-way sensitivity analysis indicated that varying the vaccine price differential had the largest effect on the incremental cost-effectiveness ratio, and then AOM parameters. Probabilistic sensitivity analysis predicted PHiD-CV to be dominant over PCV13 in 92.4% of simulations.
Conclusions:
Any difference in price between PHiD-CV and PCV13 is expected to be the key driver of vaccine choice for preventing childhood pneumococcal disease in Turkey. At price parity, PHiD-CV use is likely to be a dominant strategy over the use of PCV13.
Related Concept Videos
Vaccinations
Conjugated Proteins
Nucleoproteins are protein complexes that contain nucleic acids, categorized as deoxyribonucleoproteins (DNPs) or ribonucleoproteins (RNPs) respectively. The nucleosome is a typical example of a DNP where nuclear DNA is associated with histone proteins. The major antigen for the Covid-19 virus SARS-CoV is an RNP that is critical...
Conjugated Proteins
Buffer Effectiveness
The buffer capacity is the amount of acid or base that can be added to a given volume...
Conjugation
The Sense of Self: Reflected Self-Appraisal and Social Comparison

